Home / Press / CMS Hasche Sigle advises Curetis AG on Series B round...

CMS Hasche Sigle advises Curetis AG on Series B round of financing

22/04/2013

Munich – Molecular diagnostics company Curetis AG has completed a Series B round of financing totalling EUR 12.5 million. The firm is based in Holzgerlingen, near Stuttgart. Lead investor with EUR 6 million is HBM Partners. It is a world-leading investor in the healthcare/medical sector and will now appoint a member to the supervisory board. The current institutional investors, aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture and KfW, also invested a total of EUR 5.6 million on a pro rata basis. Stakes were also taken by the management of Curetis as well as several founders of the company, private investors and supervisory board members.

A team from CMS Hasche Sigle led by Stefan-Ulrich Müller advised Curetis on all legal aspects of the round of financing.

The current round means that the company, established in 2007, has so far raised a total of EUR 49.1 million in venture capital. In addition to expanding the international sales network, the new capital is earmarked primarily for developing the rapid Unyvero™ system. This enables a number of bacteria and antibiotic resistances to be identified in one cycle, on the basis of a single sample. The funding will be used to finance an important study as a requirement for US market launch, as well as upcoming market penetration in Germany, Austria and Switzerland.

CMS Hasche Sigle

Stefan-Ulrich Müller, Corporate, Lead Partner
Sebastian Wilhelm, Corporate
Stefan Lehr, Competition

Press Contact
presse@cms-hs.com

time lapse of train
Press releases
Press Release Curetis, 22/04/2013
Download
PDF 99.1 kB

Related people

Portrait ofStefan-Ulrich Müller
Stefan-Ulrich Müller, M. Jur. (Oxford)
Partner
Munich
Portrait ofStefan Lehr
Stefan Lehr
Partner
Frankfurt